Doximity, which ranks fifth on the IBD 50, crushed December-quarter expectations late Thursday and raised its outlook for the ...
Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback